Výsledky vyhledávání

Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report

Autor: Gitelman, Stephen, Wherrett, DK, Chiang, JL, Delamater, AM, Dimeglio, LA, Gitelman, SE, Gottlieb, PA, Herold, KC, Lovell, DJ, Orchard, TJ, Ryan, CM

Publikováno v: Gitelman, Stephen; Wherrett, DK; Chiang, JL; Delamater, AM; Dimeglio, LA; Gitelman, SE; et al.(2015). Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/4wm074bk

© 2015 by the American Diabetes Association.Emerging data suggest that type 1 diabetes is a more aggressive disease in children than in adults, with important differences in pathophysiology and clinical course. Therefore, the efficacy of disease-mod

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::415d6446b172fb9a23a3a4079a0180b4
http://www.escholarship.org/uc/item/4wm074bk

Zobrazit plný text záznamu

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders

Autor: Herold, KC, Gitelman, SE, Ehlers, MR, Gottlieb, PA, Greenbaum, CJ, Hagopian, W, Boyle, KD, Keyes-Elstein, L, Aggarwal, S, Phippard, D, Sayre, PH, McNamara, J, Bluestone, JA

Publikováno v: Diabetes Technology and Therapeutics, vol 16, iss SUPPL. 1
Herold, KC; Gitelman, SE; Ehlers, MR; Gottlieb, PA; Greenbaum, CJ; Hagopian, W; et al.(2014). Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes Technology and Therapeutics, 16(SUPPL. 1), S86-S87. doi: 10.1089/dia.2014.1510. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/0bc480zj
Herold, KC; Gitelman, SE; Ehlers, MR; Gottlieb, PA; Greenbaum, CJ; Hagopian, W; et al.(2013). Teplizumab (Anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes, 62(11), 3766-3774. doi: 10.2337/db13-0345. UCSF: Retrieved from: http://www.escholarship.org/uc/item/2t80r87v

Trials of immune therapies in new-onset type 1 diabetes (T1D) have shown success, but not all subjects respond, and the duration of response is limited. Our aim was to determine whether two courses of teplizumab, an Fc receptor-nonbinding anti-CD3 mo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::a802baca9c3a40eee13c3101f723528b
https://escholarship.org/uc/item/0bc480zj

Zobrazit plný text záznamu

Fall in C-peptide during first 2 years from diagnosis: Evidence of at least two distinct phases from composite type 1 diabetes trialnet data

Autor: Gitelman, Stephen, Greenbaum, CJ, Beam, CA, Boulware, D, Gitelman, SE, Gottlieb, PA, Herold, KC, Lachin, JM, McGee, P, Palmer, JP, Pescovitz, MD

Publikováno v: Gitelman, Stephen; Greenbaum, CJ; Beam, CA; Boulware, D; Gitelman, SE; Gottlieb, PA; et al.(2012). Fall in C-peptide during first 2 years from diagnosis: Evidence of at least two distinct phases from composite type 1 diabetes trialnet data. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/6gp948bd

Interpretation of clinical trials to alter the decline in β-cell function after diagnosis of type 1 diabetes depends on a robust understanding of the natural history of disease. Combining data from the Type 1 Diabetes TrialNet studies, we describe t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::560d38ea3fefa07f3214f3dab8899095
http://www.escholarship.org/uc/item/6gp948bd

Zobrazit plný text záznamu

Erratum

Autor: Atkinson, MA, Bluestone, JA, Eisenbarth, GS, Hebrok, M, Herold, KC, Accili, D, Pietropaolo, M, Arvan, PR, Von Herrath, M, Markel, DS, Rhodes, CJ

Publikováno v: Diabetes, vol 61, iss 6

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::6320f90a7aeb0edc930995a94eff149b
https://escholarship.org/uc/item/8735z1c9

Zobrazit plný text záznamu

How does type 1 diabetes develop? The notion of homicide or β-cell suicide revisited (Diabetes (2011) 60, (1370-1379))

Autor: Atkinson, MA, Bluestone, JA, Eisenbarth, GS, Hebrok, M, Herold, KC, Accili, D, Pietropaolo, M, Arvan, PR, Von Herrath, M, Markel, DS, Rhodes, CJ

Publikováno v: Diabetes, vol 61, iss 6
Atkinson, MA; Bluestone, JA; Eisenbarth, GS; Hebrok, M; Herold, KC; Accili, D; et al.(2012). How does type 1 diabetes develop? The notion of homicide or β-cell suicide revisited (Diabetes (2011) 60, (1370-1379)). Diabetes, 61(6), 1648. doi: 10.2337/db12-er06a. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/8735z1c9

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::192e936e04b0a8b132858874b4aaae21
https://escholarship.org/uc/item/8735z1c9

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání